{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:15:32Z","timestamp":1778523332485,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Proton pump inhibitors (PPIs) serve as the primary treatment for acid-related disorders, such as gastroesophageal reflux disease and peptic ulcer disease. Although PPIs are regarded as the first-line medication for acid suppression, they have notable limitations, including the need for acid-mediated activation, a short half-life and duration of action, and metabolic variability. Zastaprazan is a newly developed potassium-competitive acid blocker (P-CAB) that competitively and reversibly inhibits acid production and secretion. Like other P-CABs, zastaprazan exhibits pharmacodynamic and pharmacokinetic properties that differs significantly from those of PPIs. These differences offer potential advantages, such as rapid, robust, and long-standing acid suppression, the lack of CYP2C19 metabolism, and no need for conversion into an active form. Completed clinical trials of zastaprazan have demonstrated comparable or superior efficacy to that of PPIs for the healing of erosive esophagitis and gastric ulcers without concerning safety signals. Notably, in erosive esophagitis, zastaprazan 20 mg demonstrated faster healing at week 4 compared to esomeprazole 40 mg, whereas in gastric ulcers, zastaprazan 20 mg achieved a 100% healing rate at 8 weeks compared to 97.1% with lansoprazole 30 mg. Zastaprazan is approved in the Republic of Korea for the treatment of erosive esophagitis and gastric ulcer and is undergoing phase III clinical trials for the prevention of non-steroidal anti-inflammatory drug-induced peptic ulcer and the treatment of non-erosive reflux disease. In this review, we summarize and discuss the pharmacology, efficacy, and safety of zastaprazan in acid-related disorders.<\/jats:p>","DOI":"10.3390\/jcm15103700","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:17:42Z","timestamp":1778519862000},"page":"3700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zastaprazan, a Novel Potassium-Competitive Acid Blocker, for Acid-Related Disorders"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-5734","authenticated-orcid":false,"given":"Gwang Ha","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Chan","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-6398","authenticated-orcid":false,"given":"Moon Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis","volume":"67","author":"Eusebi","year":"2018","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Xie, X., Ren, K., Zhou, Z., Dang, C., and Zhang, H. (2022). The global, regional and national burden of peptic ulcer disease from 1990 to 2019: A population-based study. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02130-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3748\/wjg.v11.i26.4067","article-title":"Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis","volume":"11","author":"Wang","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e8120","DOI":"10.1097\/MD.0000000000008120","article-title":"Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5056\/jnm25128","article-title":"2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy","volume":"32","author":"Huh","year":"2026","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal","volume":"37","author":"Savarino","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1007\/s10620-020-06814-1","article-title":"Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice","volume":"66","author":"Harris","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5056\/jnm24159","article-title":"Potassium-competitive Acid Blockers for Treatment of Extraesophageal Symptoms and Signs","volume":"31","author":"Kim","year":"2025","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","article-title":"Esomeprazole versus other proton pump inhibitors in erosive esophagitis: A meta-analysis of randomized clinical trials","volume":"4","author":"Gralnek","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e14075","DOI":"10.1111\/nmo.14075","article-title":"ESNM\/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease","volume":"33","author":"Zerbib","year":"2021","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/ctg.2015.39","article-title":"Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?","volume":"6","author":"Hunt","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5056\/jnm24024","article-title":"Treatment Response with Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis","volume":"30","author":"Seo","year":"2024","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","article-title":"Review article: Potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Metz","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40265-024-02057-w","article-title":"Zastaprazan: First Approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e01090","DOI":"10.1002\/prp2.1090","article-title":"JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases","volume":"11","author":"Ku","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/apt.17406","article-title":"Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects","volume":"57","author":"Hwang","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, X., Deng, D., Meng, J., Hu, H., Zhuang, Q., Zhou, X., Fu, L., Fan, B., Xu, X., and Huang, Q. (2025). Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [(14)C]JP-1366. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1701581"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, J., and Hahn, J. (2025). Clinical pharmacokinetics of potassium competitive acid blockers: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1580969"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00228-023-03521-4","article-title":"Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease","volume":"79","author":"Ramani","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/psp4.13228","article-title":"Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers","volume":"13","author":"Yang","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/apt.14818","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects","volume":"48","author":"Sunwoo","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.2174\/1389200217666160322143857","article-title":"Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors","volume":"17","author":"Yang","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: The clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lee, M.S., Lee, J., Pang, M., Kim, J., Cha, H., Cheon, B., Choi, M.K., Song, I.S., and Lee, H.S. (2024). In Vitro Metabolism and Transport Characteristics of Zastaprazan. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16060799"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.112.045575","article-title":"Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: Focus on cytochrome P450 2C19","volume":"40","author":"Zvyaga","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/apt.16121","article-title":"Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects","volume":"52","author":"Sunwoo","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.12793\/tcp.2025.33.e10","article-title":"Evaluation of drug-drug interaction potentials between JP-1366 and celecoxib using physiologically based pharmacokinetic modeling","volume":"33","author":"Choi","year":"2025","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.14309\/ajg.0000000000002929","article-title":"Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis","volume":"120","author":"Oh","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Park, K.S., Kim, H.S., Oh, J.H., Chung, W.C., Choi, S.C., Lee, S.H., Kim, T.H., Cheung, D.Y., Baik, G.H., and Kim, S.M. (2026). Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers. Gut Liver, 20.","DOI":"10.5009\/gnl250334"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.5009\/gnl220457","article-title":"Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis","volume":"17","author":"Kim","year":"2023","journal-title":"Gut Liver"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2544886","DOI":"10.1080\/07853890.2025.2544886","article-title":"Research progress of potassium-competitive acid blockers in the treatment of Helicobacter pylori","volume":"57","author":"Ma","year":"2025","journal-title":"Ann. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.5009\/gnl220218","article-title":"Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study","volume":"17","author":"Jung","year":"2023","journal-title":"Gut Liver"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fernandez-Gonzalez, S.M., Moreno-Alvarez, A., and Solar-Boga, A. (2024). Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials. Children, 11.","DOI":"10.20944\/preprints202401.2222.v1"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:44:50Z","timestamp":1778521490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103700"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103700","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}